Motor and Cognitive Training With the Rehabilitation Gaming System for Patients Affected by Cerebral Palsy

Universitat Pompeu Fabra1 site in 1 country14 target enrollmentNovember 2016

ConditionsCerebral Palsy Movement Disorder

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Cerebral Palsy
Sponsor: Universitat Pompeu Fabra
Enrollment: 14
Locations: 1
Primary Endpoint: Change in motor function of the affected extremity as measured by MACS clinical scale
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

In this study the investigators evaluate the effectivity of Virtual Reality-based rehabilitation protocols for preventing motor deterioration in patients with cerebral palsy.

Registry

clinicaltrials.gov

Start Date

November 2016

End Date

May 2018

Last Updated

7 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Universitat Pompeu Fabra

Responsible Party

Principal Investigator

Paul Verschure

PhD

Universitat Pompeu Fabra

Eligibility Criteria

Inclusion Criteria

•Children and Adult patients between 12- 50 years old diagnosed with CP according to Gross Motor Function Classification System (GMFCS). Level of disability between I and IV.
•Ashworth modified clinical scale \< 3 (Ashworth, 1964, Bohannon Bohannon and Smith, 1987).

Exclusion Criteria

•Severe visual impairment.
•Severe cognitive impairment such as mental retardation which impedes the understanding of the task.

Outcomes

Primary Outcomes

Change in motor function of the affected extremity as measured by MACS clinical scale

Time Frame: Change from Baseline to week 5 (End of Treatment)

Secondary Outcomes

Change in motor function of the affected extremity as measured by the Box and Blocks clinical scale(Change from Baseline to week 5 (End of Treatment))
Change in the amount of use of the affected arm during training as measured by the Virtual Reality system(Change from Baseline to week 5 (End of Treatment))
Change in attention and visuo-perceptive and visuo-constructional apraxia as measured by the WAIS-III scale(Change from Baseline to week 5 (End of Treatment))